Table of Contents
|
Preface |
xi |
|
|
Dedication |
xii |
|
|
Abbreviations |
xiii |
|
|
PART 1 |
GENERAL DERMATOLOGY |
|
|
Work-up Quick Reference |
3 |
|
|
Direct Immunofluorescence
- Where to Biopsy? |
3 |
|
|
False
Positive/Negative Difs |
4 |
|
|
Biopsy for GVHD |
4 |
|
|
The Dermatologic Differential
Algorithm |
4 |
|
|
Alopecia Work-Up |
5 |
|
|
Associations |
5 |
|
|
Cicatricial or Non-Cicatricial? |
5 |
|
|
Aphthosis Classification and
Workup |
9 |
|
|
Morphologic
Classification |
9 |
|
|
Classification By
Cause |
9 |
|
|
Work-Up for Complex Apthae |
9 |
|
|
Treatment |
9 |
|
|
Amyloidoses |
10 |
|
|
Xanthomas |
11 |
|
|
Hyperlipoproteinemias: Fredrickson
Classification |
12 |
|
|
Histiocytosis |
13 |
|
|
Lupus Erythematosus |
17 |
|
|
Systemic Lupus Erythematosus
Criteria (4 of 11) |
17 |
|
|
Acute Cutaneous
Lupus Erythematosus |
17 |
|
|
Subacute Cutaneous
Lupus Erythematosus |
17 |
|
|
Chronic Cutaneous
Lupus Erythematosus |
17 |
|
|
Autoantibody
Sensitivities and Specificities |
18 |
|
|
Antinuclear Antibodies |
20 |
|
|
Autoantibodies in Connective
Tissue Diseases |
21 |
|
|
Vasculitis |
22 |
|
|
Treatment of
ANCA-Associated Vasculitis |
22 |
|
|
Anti-Neutrophil
Cytoplasmic
Antibody |
23 |
|
|
Small Vessel Vasculitis |
24 |
|
|
Medium (± Small)
Vessel Vasculitis |
26 |
|
|
Large Vessel Vasculitis |
27 |
|
|
Cryoglobulinemia |
28 |
|
|
CTCL Classification |
29 |
|
|
Mycosis Fungoides
Variants |
29 |
|
|
MF (TNMB) Staging |
31 |
|
|
MF Treatment
Algorithm |
32 |
|
|
Cutaneous B-Cell Lymphoma |
33 |
|
|
Leukemia Cutis |
33 |
|
|
Monoclonal Gammopathies |
34 |
|
|
Melanoma – Classification |
35 |
|
|
Breslow Depth |
36 |
|
|
Melanoma – Staging
and Survival |
36 |
|
|
Melanoma – Treatment
Guidelines |
37 |
|
|
Infectious Disease |
39 |
|
|
Viruses and Diseases |
39 |
|
|
Human Papiliomavirus |
41 |
|
|
Other Viral Diseases |
42 |
|
|
Mycoses |
45 |
|
|
Vector-Borne Diseases |
52 |
|
|
Creatures in
Dermatology |
58 |
|
|
Immunology |
63 |
|
|
Complement |
63 |
|
|
Complement
Deficiencies |
64 |
|
|
Angioedema and Complement
Levels |
64 |
|
|
Th Profiles |
65 |
|
|
Bullous Disorders |
65 |
|
|
Intracorneal/Subcorneal |
65 |
|
|
Intraepidermal Blisters |
66 |
|
|
Suprabasilar Blisters |
66 |
|
|
Subepidermal with Little
Inflammation |
66 |
|
|
Subepidermal with Lymphocytes |
67 |
|
|
Subepidermal with Eosinophils |
67 |
|
|
Subepidermal with Neutrophils |
67 |
|
|
Subepidermal with Mast Cells |
68 |
|
|
Epidermolysis Bullosa |
68 |
|
|
Major Bullous
Diseases - Clinicopathologic Findings |
71 |
|
|
Glands |
75 |
|
|
Disorders or Drugs Associated with
Skeletal, Ocular, and/or Nail Findings |
77 |
|
|
Dermatoses of Pregnancy |
88 |
|
|
Neonatal Vesiculopustular
Eruptions |
90 |
|
|
Genital Ulcers |
95 |
|
|
Common Contact Allergens |
96 |
|
|
Features Suggestive
of Specific Irritant/Toxin |
100 |
|
|
Plants and Dermatoses |
100 |
|
|
Vitamin Deficiencies/Hypervitaminoses |
103 |
|
|
Genodermatoses |
107 |
|
|
Gene List |
107 |
|
|
Chromosome
Abnormalities |
133 |
|
|
Tumors |
134 |
|
|
Disorders of Cornification |
136 |
|
|
Disorders of Hair,
Nail, Ectoderm |
139 |
|
|
Tumor Syndromes |
144 |
|
|
Disorders of
Connective Tissue |
146 |
|
|
Disorders of
Metabolism |
149 |
|
|
Disorders of
Pigmentation |
154 |
|
|
Disorders of Vascularization |
156 |
|
|
Immunodeficiency
Syndromes |
159 |
|
|
Miscellaneous |
162 |
|
|
Dermoscopy |
163 |
|
|
Pathology |
165 |
|
|
Histochemical Staining |
165 |
|
|
Immunohistochemical Staining |
167 |
|
|
Pathologic Bodies |
170 |
|
|
Other Derm
Path Buzzwords, Patterns, DDx |
175 |
|
|
PART 2 |
SURGERY |
|
|
Surgical Margins Guidelines |
183 |
|
|
Indications for Mohs
Micrographic Surgery |
183 |
|
|
Guideline for Prophylactic Antibiotics |
184 |
|
|
Algorithm for
Antibiotic Prophylaxis |
185 |
|
|
Guideline for Prophylactic Antivirals |
186 |
|
|
Anesthetics |
186 |
|
|
Dose Calculation |
186 |
|
|
Tumescent Anesthesia |
186 |
|
|
Topical Anesthetic |
187 |
|
|
Adverse Reaction to
Local Anesthetics |
187 |
|
|
Local Anesthetic |
188 |
|
|
Nerve Blocks |
189 |
|
|
Surgical Anatomy |
189 |
|
|
Anatomy of the Face |
189 |
|
|
Anatomy of the Nail |
193 |
|
|
Danger Zones in
Surgery |
194 |
|
|
Dermatomal Distribution of
Sensory Nerves |
196 |
|
|
Anatomy of the Lower
Extremity Venous System |
197 |
|
|
Cutaneous Reconstruction |
198 |
|
|
Undermining Depths
in Reconstruction |
199 |
|
|
Dangerzone of the Neck: Erbs
Point |
196 |
|
|
Second Intention |
199 |
|
|
Simple Linear Closure |
200 |
|
|
Transposition Flap |
201 |
|
|
Advancement Flap |
204 |
|
|
Interpolation Flap |
206 |
|
|
Rotation Flap |
207 |
|
|
Skin Graft |
208 |
|
|
Sutures |
210 |
|
|
Absorbable |
210 |
|
|
Non-Absorbable |
211 |
|
|
Suture Removal Time |
212 |
|
|
Electrosurgery |
212 |
|
|
Wound Healing |
212 |
|
|
Wound Dressing |
213 |
|
|
Antiseptic Scrubs |
214 |
|
|
Lasers |
216 |
|
|
Laser Principles |
217 |
|
|
Thermal Relaxation
Time |
217 |
|
|
Laser Treatment of
Tattoo Pigment |
218 |
|
|
Photoinduced Eye Injury |
218 |
|
|
Photodynamic Therapy |
220 |
|
|
Basic Principles |
220 |
|
|
Applications |
220 |
|
|
Photosensitizer Properties and
Options |
220 |
|
|
UV Spectrum |
222 |
|
|
UV Protection Measurements |
223 |
|
|
UV Associations/Specificities |
223 |
|
|
Glogau Wrinkle Scale |
224 |
|
|
Fitzpatrick Skin Type |
224 |
|
|
Peeling Agents |
224 |
|
|
TCA Peel |
225 |
|
|
TCA Peel Frost Level |
225 |
|
|
Jessner Solution |
225 |
|
|
Baker-Gordon Phenol |
226 |
|
|
Cook Total Body Peel |
226 |
|
|
Pre-Peel Prep |
226 |
|
|
Post-Peel Wound Care |
226 |
|
|
Botulinum Toxin |
226 |
|
|
Botox Injection Sites |
227 |
|
|
Fillers |
229 |
|
|
Sclerotherapy |
234 |
|
|
Determine Vessel
Size Using Needle Gauge |
236 |
|
|
Recommended Maximum
Effective Concentration of Sclerosant to Minimize Side
Effects |
236 |
|
|
PART 3 |
DRUGS AND THERAPIES |
|
|
Medication Quick Reference |
239 |
|
|
Topical Steroids |
239 |
|
|
Non-Steroidals |
240 |
|
|
Commonly Used Drugs
in Dermatology |
240 |
|
|
Systemic Medications |
243 |
|
|
Antimalarials |
243 |
|
|
Immunosuppressive
Agents |
244 |
|
|
Systemic Retinoids |
246 |
|
|
Biologics |
247 |
|
|
General Reference |
249 |
|
|
Metric Measurements |
249 |
|
|
Dosage Calculation |
249 |
|
|
Drug Dispensing and
Absorption |
249 |
|
|
Corticosteroid |
249 |
|
|
Acne – Topical |
250 |
|
|
Antibiotics |
250 |
|
|
Keratolytics |
250 |
|
|
Acne – Systemic |
251 |
|
|
Antibiotics |
251 |
|
|
Retinoids |
252 |
|
|
Others |
252 |
|
|
Alopecia |
252 |
|
|
Analgesics |
252 |
|
|
Anesthetics–Topical |
253 |
|
|
Antibiotics |
253 |
|
|
Topical/Antiseptic |
253 |
|
|
Systemic |
254 |
|
|
Antibiotic
Preoperative Prophylaxis, See p. 184 |
|
|
|
Antibiotic Regimens |
255 |
|
|
STDs |
257 |
|
|
Antifungals |
257 |
|
|
Topical |
257 |
|
|
Systemic |
258 |
|
|
Antifungal Regimens |
260 |
|
|
Antiparasitics |
261 |
|
|
Antivirals |
262 |
|
|
For HSV Labialis
– Topical Agents |
262 |
|
|
For HSV 1 or 2 –
Oral Agents |
262 |
|
|
For HSV Disseminated
Disease |
262 |
|
|
For Herpes Zoster/VZV |
262 |
|
|
For Genital Warts |
263 |
|
|
For Verruca
Vulgaris |
263 |
|
|
For Molluscum |
263 |
|
|
Antihistamines |
263 |
|
|
Sedating |
263 |
|
|
Non-Sedating |
264 |
|
|
H2-Blockers |
264 |
|
|
Antipruritic |
264 |
|
|
Topical |
264 |
|
|
Oral |
264 |
|
|
Bleaching Agents/Depigmenting
Agents |
265 |
|
|
Topical Chemotherapy |
266 |
|
|
Actinic Keratoses
(AK) |
266 |
|
|
Basal Cell Carcinoma
(BCC) - Superficial BCC |
266 |
|
|
CTCL |
266 |
|
|
Topical Agents |
266 |
|
|
Oral Agent |
266 |
|
|
Other Agent |
267 |
|
|
Psoriasis |
267 |
|
|
Topical Agents |
267 |
|
|
Tar |
267 |
|
|
Systemic Agents |
267 |
|
|
Seborrheic Dermatitis |
268 |
|
|
Hypertrichosis |
268 |
|
|
Hyperhidrosis |
268 |
|
|
Wound Care |
269 |
|
|
Vitamins/Nutritional Supplements |
269 |
|
|
Miscellaneous Meds |
269 |
|
|
Cytochrome P-450 Interactions |
270 |
|
|
Pregnancy Categories of Commonly Used
Dermatologic Agents |
272 |
|
|
Common Dermatologic Drugs and Teratogenic
Effects |
273 |
|
|
Dermatologic Drugs Reportedly Associated
with Contraceptive Failure |
273 |
|
|
Drug Eruptions |
274 |
|
|
Chemotherapeutic Agents and Skin
Changes |
277 |
|
|
Antidote to Extravasation
of Chemotherapeutic Agents |
279 |
|
|
UV Light Treatment |
279 |
|
|
UVA/UVB Dosing |
279 |
|
|
NBUVB Dosing |
280 |
|
|
PUVA |
280 |
|
|
|
282 |
|
|
Diagnosis of TEN |
282 |
|
|
Triage Algorithm for
TEN Patients |
283 |
|
|
Treatment for All
TEN Patients |
283 |
|
|
Index |
287 |
|